Piyasa kapalı· · HKD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
Australia’s inflation rate recently reached 4%, and the Reserve Bank lifted its cash rate target to 4.60%, partly linked to the artificial intelligence boom. Higher funding costs can pressure many sectors. Healthcare groups using AI to improve diagnoses, tailor treatments and run hospitals more efficiently could still attract attention. This article highlights three Australian AI healthcare stocks from our focused screener that investors may want on their watchlist. The three stocks below are...
The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these targets to how effectively Amneal Pharmaceuticals turns its new products, biosimilars platform, and recent acquisitions into durable earnings power. As you read on, you will see how this evolving narrative may shape your own view of the stock’s...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.